ScholarIQanswers from OpenAlex
Astellas Pharma
FunderResearch funding and supported work
Astellas Pharma is a funder indexed in ScholarIQ from OpenAlex.
What is known about Astellas Pharma?
ScholarIQrecord summary
company
How many works does Astellas Pharma have?
ScholarIQindexed works
Astellas Pharma has 16,645 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
What is the OpenAlex record for Astellas Pharma?
ScholarIQopenalex
The OpenAlex for Astellas Pharma is on the source record.
What is the ROR of Astellas Pharma?
ScholarIQror
The ROR for Astellas Pharma is on the source record.
What are the most-cited papers on Astellas Pharma?
ScholarIQmost cited works
Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases
Brad H. Rovin, Sharon G. Adler, Jonathan Barratt, Frank Bridoux, Kelly A. Burdge, Tak Mao Chan, H. Terence Cook, Fernando C. Fervenza, Keisha L. Gibson, Richard J. Glassock, David Jayne, Vivekanand Jha, Adrian Liew, Zhi-Hong Liu, Juan M. Mejía‐Vilet, Carla Nester, Jai Radhakrishnan, Elizabeth M. Rave, Heather N. Reich, Pierre Ronco, Jan‐Stephan Sanders, Sanjeev Sethi, Yusuke Suzuki, Sydney Tang, Vladimı́r Tesař, Marina Vivarelli, Jack F.M. Wetzels, Lyubov Lytvyn, Jonathan C. Craig, David J. Tunnicliffe, Martin Howell, Marcello Tonelli, Michael Cheung, Amy Earley, Jürgen Floege
Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial
Bertram Pitt, Lars Køber, Piotr Ponikowski, Mihai Gheorghiade, Gerasimos Filippatos, Henry Krum, Christina Nowack, Peter Kolkhof, So Young Kim, Faı̈ez Zannad
Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups
Kenneth W. Mahaffey, Meg Jardine, Séverine Bompoint, Christopher P. Cannon, Bruce Neal, Hiddo J.L. Heerspink, David M. Charytan, Robert Edwards, Rajiv Agarwal, George L. Bakris, Scott Bull, George Capuano, Dick de Zeeuw, Tom Greene, Adeera Levin, Carol A. Pollock, Tao Sun, David C. Wheeler, Yshai Yavin, Hong Zhang, Bernard Zinman, Norman Rosenthal, Barry M. Brenner, Vlado Perkovic, On behalf of the CREDENCE Study Investigators
Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial
Helen M. Colhoun, Ildiko Lingvay, Paul Brown, John Deanfield, Kirstine Brown‐Frandsen, Steven E. Kahn, Jorge Plutzky, Koichi Node, Alexander Parkhomenko, Lars Rydén, John Wilding, Johannes F.E. Mann, Katherine R. Tuttle, Thomas Idorn, Naveen Rathor, A. Michael Lincoff
A comparative post hoc analysis of finerenone and spironolactone in resistant hypertension in moderate-to-advanced chronic kidney disease
Rajiv Agarwal, Bertram Pitt, Biff F. Palmer, Csaba P. Kövesdy, Ellen Burgess, Gerasimos Filippatos, Jolanta Małyszko, Luís M. Ruilope, Patrick Rossignol, Peter Rossing, Roberto Pecoits‐Filho, Stefan D. Anker, Amer Joseph, Robert Lawatscheck, Daniel J. Wilson, Martin Gebel, George L. Bakris